T. Rowe Price Investment Management
JSPR icon

T. Rowe Price Investment Management’s Jasper Therapeutics JSPR Stock Holding History

T. Rowe Price Investment Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-964,754
Closed -$1.77M – 804
2025
Q4 		$1.77M Sell
964,754
-64,052
-6% -$129K ﹤0.01% 630
2025
Q3 		$2.45M Buy
1,028,806
+325,158
+46% +$986K ﹤0.01% 605
2025
Q2 		$3.91M Buy
703,648
+891
+0.1% +$4.39K ﹤0.01% 586
2025
Q1 		$3.02M Buy
702,757
+620,592
+755% +$4.13M ﹤0.01% 597
2024
Q4 		$1.76M Buy
+82,165
New +$1.71M ﹤0.01% 592

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

T. Rowe Price Investment Management's JSPR Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 964,754 shares — an estimated $1.77M sold.

T. Rowe Price Investment Management first reported a position in JSPR in Q4 2024 and held it in 5 quarters. The position peaked at $3.91M in Q2 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 964,754 Jasper Therapeutics shares in Q1 2026, an estimated $1.77M.
  • T. Rowe Price Investment Management first reported a position in Jasper Therapeutics in Q4 2024 and held it in 5 quarters.
  • T. Rowe Price Investment Management's Jasper Therapeutics position peaked at $3.91M in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.